 | This is not a Wikipedia article: It is an individual user's work-in-progress page, and may be incomplete and/or unreliable. |
John V. Oyler | |
|---|---|
| Born | 1968 |
| Nationality | American |
| Alma mater | B.A., Massachusetts Institute of Technology; M.B.A., Stanford Graduate School of Business |
| Occupation | business executive |
| Organization | Board Member of Biotechnology Innovation Organization (BIO) |
| Known for | co-founder, Chairman and CEO of BeiGene |
John V. Oyler (born 1968) is the Co-Founder, Chairman and CEO of BeiGene, the global oncology pharmaceutical company.[1] He is a board member of Biotechnology Innovation Organization (BIO).[2]
Early life and education
editOyler was born and raised in Pittsburgh,Pennsylvania. He attended Mt. Lebanon High School where he first developed his interest in science.[3] His scientific research and presentations won awards from Westinghouse two years in a row.[4][5]
He started his first business while doing his undergraduate degree in engineering at Massachusetts Institute of Technology, selling and renting student supplies in the Boston area.[6] Oyler's first job after his undergraduate degree was with McKinsey & Company, including a stint in the firm's Hong Kong office. While working there he earned his MBA from Stanford Graduate School of Business.[1]
Career
editOyler founded Telephia in 1997 and it sold to Nielsen Co. in 2007.[3] He started contract research organization BioDuro in 2005.[7] BioDuro sold to PPD, Inc. in 2010.[8][9][10]
Oyler co-founded BeiGene with Xiaodong Wang in 2013. Oyler invested $10 million of his own money to start BeiGene and secured funding from other angel investors and Merck & Co.; he remains the largest individual shareholder in the company.[3][11] Their explicit goal in forming BeiGene was to make life-saving oncology medications that are affordable and accessible.[12]
Oyler established BeiGene's early clinical trials in Australia as part of his efforts to expand clinical trials to areas underserved by the pharma industry.[6]
While at BeiGene, Oyler was responsible for the $900 million IPO on the NASDAQ exchange.[13] He also led the firm's $800 million investment in and move to the 42-acre research and manufacturing facility in Hopewell, New Jersey in 2024.[14][15]
References
edit- ^ a b Wright, Rob (1 November 2019). "How-and Why- John Oyler Built BeiGene". Life Science Leader.
- ^ Dai, Sarah (16 October 2017). "CEO of China oncology start-up BeiGene toils to bring drugs to fruition". South China Morning Post.
- ^ a b c Flannery, Russell (23 July 2024). "US Biotech Billionaire's Success In China Is Giving New Jersey a Boost". Forbes.
- ^ "Science winners go to international fair". The Pittsburgh Press. 6 April 1986. p. 33. Retrieved 8 August 2024 – via Newspapers.com.
- ^ "2 at Mt. Lebanon gain national science fair". The Pittsburgh Press. 3 April 1985. p. 21. Retrieved 8 August 2024 – via Newspapers.com.
- ^ a b Henderson, Lisa (29 March 2023). "A Vision of Affordability". PharmExec.
- ^ Parrish, Meagan (6 September 2022). "Entrepreneurs:John Oyler". PharmaVoice.
- ^ "PPD Completes BioDuro Acquisition". Contract Pharma. 30 November 2009.
- ^ "John Oyler". Real Time Billionaires. 27 July 2024.
- ^ "Most Promising China Life Science Companies Named at BioBay Investor Forum". Fierce Biotech. 5 November 2010.
- ^ Loo, Daryl (8 July 2011). "BeiGene Brings Biotech to China". Bloomberg.
- ^ Bergeron, Tom (23 July 2024). "BeiGene's global goal:Create great medicines- and make them accessible (and affordable) to all". ROI NJ.
- ^ Garde, Damian (15 March 2016). "The most influential people in biopharma today". Fierce Biotech.
- ^ Bergeron, Tom (23 July 2024). "BeiGene ribbon-cutting:Big get for life science industry- and bigger vote of confidence for state". ROI-NJ.
- ^ "BeiGene Opens US Biologics Manufacturing and R&D Facility in Hopewell". New Jersey Business Magazine, Life Sciences. 23 July 2024.